Ivan Kairatov, a highly respected expert in the Biopharma industry, delves into the groundbreaking findings surrounding PPP2R1A mutations in ovarian clear cell carcinoma (OCCC) and their implications for cancer treatment. With his deep understanding of biotechnology and innovation, Kairatov shares
Recent advancements in cancer research have unveiled a surprising potential therapeutic agent against one of the deadliest forms of cancer: pancreatic cancer. Central to this innovation is stevia, a plant usually celebrated for its role as a calorie-free sweetener. Now, through bacterial
Prostate cancer (PCa) remains a formidable challenge in the field of medical diagnostics, often leading to high mortality rates worldwide. Its detection primarily relies on MRI exams, which, despite being highly instrumental, present significant variability in interpretation among radiologists.
In recent years, cancer research has witnessed groundbreaking innovations that have transformed diagnostics and treatment. Central to this progress is the advent of artificial intelligence (AI), which is increasingly being integrated into oncological practices. Among the latest advancements is an
Picture the intricacies hidden within the cell—each nucleus containing a vast genome map, intricately folded into a complex three-dimensional (3D) shape. How does this hidden architecture influence the very essence of life, determining which genes are silent or expressed? The Importance of 3D DNA
The field of cancer treatment is witnessing seismic shifts as MiNK Therapeutics, a clinical-stage biotechnology firm and subsidiary of Agenus Inc., introduces groundbreaking cell-based therapies focused on treating challenging cancers. With its pioneering work on invariant natural killer T (iNKT)
